Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pfizer Sutent Review: Partial Response Could Mean Clinical Benefit In RCC Setting

This article was originally published in The Pink Sheet Daily

Executive Summary

Review documents for the targeted oncologic show FDA looking at the product’s approval for first-line renal cell carcinoma in the context of Bayer’s Nexavar approval for the same indication.

You may also be interested in...



Pfizer's Sutent Receives Dual Approvals For Kidney Cancer & Stomach Cancer

Pfizer's Sutent received accelerated approval for first-line treatment of advanced renal cell carcinoma and full approval for treatment of refractory gastrointestinal stromal tumors.

Bayer/Onyx’ Nexavar Approved For Kidney Cancer

FDA’s full approval of the oncologic indicates sorafenib for broad use by all patients with advanced renal cell carcinoma.

Spectrum’s Iso-Vorin Could Clear FDA For Osteosarcoma By First Quarter

The Irvine, Calif., firm also plans sNDAs for a colorectal cancer claim and an oral formulation of the leucovorin relative.

Topics

UsernamePublicRestriction

Register

PS064199

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel